Quest Diagnostics Incorporated 실적 발표

Thanks. Yeah, so there's a lot there, Tycho. Look, with respect to Haystack reimbursement, Novitas is the MAC that we submit to, and it did receive a PLA code. It received a reimbursement. We continue to adjudicate through Novitas and are successful there. With respect to Medicare Advantage, we're still waiting on the MOL-DX tech assessment. Once that tech assessment is complete, the first, we will be well positioned with the Medicare Advantage plans. And then, you know, look, we're having ongoing discussions with all the major payers in terms of commercial reimbursement. In some cases, we get paid. In other cases, you don't. We appeal them all. We have doctors write letters around medical necessity, and we continue to make progress on that. But the flow MRD is an ultra-sensitive flow test that has incredibly good sensitivity specificity, and we think it is very, very competitive with you know, with next-gen sequencing-based tests. We're very confident of that. We'll continue to do studies to show that. The value proposition is really around speed. So, as you know, patients with myeloma, you know, that disease moves very, very quickly. Speed is of the essence, and we can get an answer back within three days. It's also a significantly lower-cost test, so from a reimbursement standpoint, it'll offer payers a choice that will offer physicians and patients a choice to have a test that is highly comparable with the next-gen sequencing test at, again, a turnaround time that is very, very short, three days, not weeks, and with, again, ultra, you know, good sensitivity specificity. In terms of the multi-cancer early detection tests, Yes, we have a partnership with Grail. We will do the blood draws for Grail. We've listed it in our test compendium, and Grail obviously pays us to do those draws and handle the logistics for them. And then we did announce a partnership to draw for the garnet colon cancer-based blood screening test, and that will be underway later in the first quarter.

Thanks. Yeah, so there's a lot there, Tycho. Look, with respect to Haystack reimbursement, Novitas is the MAC that we submit to, and it did receive a PLA code. It received a reimbursement. We continue to adjudicate through Novitas and are successful there. With respect to Medicare Advantage, we're still waiting on the MOL-DX tech assessment. Once that tech assessment is complete, the first, we will be well positioned with the Medicare Advantage plans. And then, you know, look, we're having ongoing discussions with all the major payers in terms of commercial reimbursement. In some cases, we get paid. In other cases, you don't. We appeal them all. We have doctors write letters around medical necessity, and we continue to make progress on that. But the flow MRD is an ultra-sensitive flow test that has incredibly good sensitivity specificity, and we think it is very, very competitive with you know, with next-gen sequencing-based tests. We're very confident of that. We'll continue to do studies to show that. The value proposition is really around speed. So, as you know, patients with myeloma, you know, that disease moves very, very quickly. Speed is of the essence, and we can get an answer back within three days. It's also a significantly lower-cost test, so from a reimbursement standpoint, it'll offer payers a choice that will offer physicians and patients a choice to have a test that is highly comparable with the next-gen sequencing test at, again, a turnaround time that is very, very short, three days, not weeks, and with, again, ultra, you know, good sensitivity specificity. In terms of the multi-cancer early detection tests, Yes, we have a partnership with Grail. We will do the blood draws for Grail. We've listed it in our test compendium, and Grail obviously pays us to do those draws and handle the logistics for them. And then we did announce a partnership to draw for the garnet colon cancer-based blood screening test, and that will be underway later in the first quarter.